Our community narratives are driven by numbers and valuation.
Value any stock for free in seconds
Get alerts and valuation updates
Participate in discussions
WA
Consensus Narrative from 18 Analysts
Fluindapyr Sales And Cost-Saving Initiatives Will Support Future Performance, Yet Pricing Pressures May Persist
Key Takeaways Strong sales of new products and cost-saving initiatives are projected to drive significant revenue and improve net margins. Sale of Global Specialty Solutions will reduce debt, improve leverage, and positively impact earnings.
View narrativeUS$73.01
FV
31.3% undervalued intrinsic discount5.95%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
4 days ago author updated this narrative